Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
Joshua E HowellSuzanne A Nesbit

Abstract

Ifosfamide is metabolized by the cytochrome P450 system to its active form, ifosforamide mustard. A potential side effect is neurotoxicity, often manifesting as confusion, hallucination, or seizure. Aprepitant, a neurokinin-1 inhibitor, is recommended for highly and moderately emetogenic chemotherapy regimens and may interfere with the metabolism of ifosfamide as it inhibits CYP3A4. The objective of the study is to identify if an increase in the incidence of neurotoxicity may be associated with the use of aprepitant with concomitant ifosfamide. A retrospective study of inpatients with sarcoma who received a two or four-day regimen of MAI (mesna, doxorubicin, and ifosfamide) between January 1, 2004 and December 31, 2006 was conducted. Data collection focused on characterizing neurotoxicity of patients receiving ifosfamide with or without aprepitant. Correlation between serum creatinine, albumin, liver function tests, age, gender, and total doses of ifosfamide was examined. A total of 45 patients received ifosfamide of which 23 (51%) were male and 24 (53%) received aprepitant. All baseline characteristics were similar for those who received aprepitant versus those who did not. No significant differences were noted between patient...Continue Reading

References

Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
Jul 1, 1986·European Journal of Cancer & Clinical Oncology·C A MeanwellG Blackledge
Jan 1, 1988·Psychiatry Research·P T TrzepaczJ Greenhouse
Jul 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J H EdmonsonD R Parkinson
Dec 15, 2000·Archives of Neurology·R Tuma, L M DeAngelis
Mar 10, 2001·Clinical Pharmacokinetics·T KerbuschJ H Beijnen
Apr 20, 2005·Cancer Chemotherapy and Pharmacology·Milly E de JongeSjoerd Rodenhuis
Jun 1, 2005·American Journal of Clinical Oncology·Kevin A David, Joel Picus
Jan 5, 2006·The Annals of Pharmacotherapy·Priti N Patel
Mar 29, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J-P DurandF Goldwasser

❮ Previous
Next ❯

Citations

Jul 10, 2009·Cancer Chemotherapy and Pharmacology·Romain CoriatFrançois Goldwasser
Mar 17, 2010·Indian Pediatrics·Pooja DewanDeepika Harit
May 22, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M S Aapro, C M Walko
Mar 23, 2011·Expert Opinion on Drug Safety·Christina H Ruhlmann, Jørn Herrstedt
Aug 26, 2015·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Yin LoFe-Lin Lin Wu
Feb 28, 2016·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Anna DushenkovPaiboon Jungsuwadee
May 5, 2017·British Journal of Clinical Pharmacology·Priya PatelL Lee Dupuis
Aug 29, 2013·The Neurohospitalist·Amy A PruittMyrna R Rosenfeld
Mar 26, 2014·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Audrea H SzabaturaDavid C Fisher
Sep 18, 2009·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners· Hansen Ho, Courtney Yuen
Jun 17, 2008·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Rami B IbrahimDavid J Edwards
Jan 11, 2018·Fundamental & Clinical Pharmacology·Thomas DuflotFabien Lamoureux
Sep 24, 2015·Pediatric Blood & Cancer·Bruno FilhonJean-Pierre Vannier
May 26, 2018·Journal of Managed Care & Specialty Pharmacy·Lisa S RotensteinNancy L Keating
Feb 13, 2018·BMC Cancer·Christophe MaritazChristelle Dufour
Mar 5, 2019·Journal of Clinical Pharmacy and Therapeutics·Jeremy ChambordMaria Rios
Oct 8, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Hakan SarbayBarış Malbora
Nov 10, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Jill N Modi, Sarah K Cimino
Nov 7, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Halima AbahssainHassan Errihani

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.